BioHarvest Sciences (NASDAQ:BHST – Get Free Report) and Nanophase Technologies (OTCMKTS:NANX – Get Free Report) are both small-cap consumer staples companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.
Earnings and Valuation
This table compares BioHarvest Sciences and Nanophase Technologies”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioHarvest Sciences | $34.51 million | 1.46 | -$11.14 million | ($0.59) | -4.34 |
| Nanophase Technologies | $37.30 million | 0.00 | -$4.39 million | $0.05 | N/A |
Institutional and Insider Ownership
70.2% of Nanophase Technologies shares are held by institutional investors. 5.1% of Nanophase Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of current recommendations and price targets for BioHarvest Sciences and Nanophase Technologies, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioHarvest Sciences | 1 | 0 | 1 | 0 | 2.00 |
| Nanophase Technologies | 0 | 0 | 0 | 0 | 0.00 |
BioHarvest Sciences currently has a consensus target price of $10.00, suggesting a potential upside of 290.62%. Given BioHarvest Sciences’ stronger consensus rating and higher possible upside, equities analysts clearly believe BioHarvest Sciences is more favorable than Nanophase Technologies.
Risk and Volatility
BioHarvest Sciences has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Nanophase Technologies has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500.
Profitability
This table compares BioHarvest Sciences and Nanophase Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioHarvest Sciences | -32.54% | -76.03% | -25.30% |
| Nanophase Technologies | 5.59% | 31.49% | 6.67% |
Summary
Nanophase Technologies beats BioHarvest Sciences on 10 of the 13 factors compared between the two stocks.
About BioHarvest Sciences
BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.
About Nanophase Technologies
Nanophase Technologies Corporation, a science-driven company, develops, manufactures, and sells integrated family of nanomaterial technologies in the United States. It engages in engineered materials, formulation development, and commercial manufacturing. The company produces engineered nanomaterial products comprising antimony, bismuth, cerium, iron, and zinc oxide for use in a various markets, including surface finishing,exterior coatings, personal care, plastics, scratch resistant coatings, and textiles. It also provides skin care formulations with mineral-based UV protection under the under the Solésence brand; and advanced material products, including architectural coatings, industrial coatings, abrasion-resistant additives, plastics additives, medical diagnostics, and surface finishing technologies applications. The company was incorporated in 1989 and is headquartered in Romeoville, Illinois.
Receive News & Ratings for BioHarvest Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioHarvest Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
